Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

November 7, 2022

Study Completion Date

December 19, 2022

Conditions

Healthy

Interventions

DRUG

Apipe (Aripiprazole10 mg)

Test drug

DRUG

Abilify (Aripiprazole10 mg)

Reference drug

Trial Locations (1)

Genuine Research Center GRC, Cairo

All Listed Sponsors

collaborator

P&C Labs, Egypt

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY